Sharon M. Gohman
Dietitian and Nutritionist in Saint Paul, MN

License number
Minnesota 1124
Issued Date
Feb 15, 1996
Renew Date
Dec 1, 2000
Expiration Date
Nov 30, 2001
Category
Dietetics and Nutrition Practice
Type
Dietitian
Address
Address
Saint Paul, MN 55112

Professional information

Sharon Gohman Photo 1

Infant Formula With Free Amino Acids And Nucleotides

US Patent:
6645543, Nov 11, 2003
Filed:
Oct 7, 2002
Appl. No.:
10/266029
Inventors:
Sharon Gohman - New Brighton MN
Carol Jo Lowry - Minneapolis MN
Assignee:
Novartis Nutrition AG - Bern
International Classification:
A23L 1305
US Classification:
426601, 426656, 426801, 426658, 514 45, 514 46
Abstract:
A fat-rich powder provides the complete nutritional needs of an at-risk infant no more than one year old, who has acquired a milk allergy, such as cows milk allergy (“CMA”), and/or an allergy to protein in “soy milk”, as well as digestive or absorption problems resulting in a damaged gut. Because such an infant must derive all its protein from amino acids it is not fed any ingredient derived from mammalian milk, but a combination of amino acids with nucleotides in specified amounts along with free L-glutamine, maintaining specified ratios of their relative amounts, which ratios in the ranges stated are found to be beneficial for healing of the infants damaged gut, and for promoting cell division to assure its normal growth. A typical feeding of 32. 6 gm of the powder delivers 160 cals; the powder, including triglycerides of relatively long chain fatty acids which contribute about 50% of the total caloric content of the powder, is nevertheless solubilized when the powder is manually shaken at 35° C.


Sharon Gohman Photo 2

Infant Formula With Free Amino Acids And Nucleotides

US Patent:
6511696, Jan 28, 2003
Filed:
Dec 13, 2000
Appl. No.:
09/735884
Inventors:
Sharon Gohman - New Brighton MN
Carol Jo Lowry - Minneapolis MN
Assignee:
Novartis Nutrition AG - Berne
International Classification:
A23L 1305
US Classification:
426601, 426656, 426801, 426658, 514 45, 514 46
Abstract:
A fat-rich powder provides the complete nutritional needs of an at-risk infant no more than one year old, who has acquired a milk allergy, such as cows milk allergy (“CMA”), and/or an allergy to protein in “soy milk”, as well as digestive or absorption problems resulting in a damaged gut. Because such an infant must derive all its protein from amino acids it is not fed any ingredient derived from mammalian milk, but a combination of amino acids with nucleotides in specified amounts along with free L-glutamine, maintaining specified ratios of their relative amounts, which ratios in the ranges stated are found to be beneficial for healing of the infants damaged gut, and for promoting cell division to assure its normal growth. A typical feeding of 32. 6 gm of the powder delivers 160 cals; the powder, including triglycerides of relatively long chain fatty acids which contribute about 50% of the total caloric content of the powder, is nevertheless solubilized when the powder is manually shaken at 35° C.


Sharon Gohman Photo 3

Oral Arginine And Insulin Secretion

US Patent:
6143786, Nov 7, 2000
Filed:
Feb 2, 1999
Appl. No.:
9/241459
Inventors:
Sharon Marie Gohman - New Brighton MN
Lester David Michels - Eden Prairie MN
Norman Alan Greenberg - New Hope MN
David Curtis Egberg - Shorewood MN
Assignee:
Novartis Nutrition AG - Berne
International Classification:
A61K 31195
US Classification:
514565
Abstract:
A therapeutically effective amount of L-arginine, or a physiologically acceptable salt thereof, is orally administered, preferably as a food supplement in combination with a meal approved by the American Diabetes Association Inc. ("ADA"), to a person having Type II diabetes mellitus but who is not on either insulin or other medication for glycemic control. When 3 g to 15 g of L-arginine is ingested concurrently with a meal, or immediately prior to eating a meal, the L-arginine decreases the concentration of insulin generated, compared to that generated after the same meal without the L-arginine; at the same time, concentration of glucose in the person's blood is decreased, indicating that available insulin sensitizes cells so as to nearly mimic the effectiveness of normal cells in a non-diabetic person; from 3 g to 15 g of orally ingested L-arginine, by itself, produces no measurable increase in insulin secretion in a diabetic.